Evaluation of biologically synthesized Au-CuO and CuO-ZnO nanoparticles against glioma cells and microorganisms

Due to the search for new methods of producing bimetallic nanoparticles, in this work, we have conducted a biological synthesis of Au-CuO and CuO-ZnO nanoparticles using Cnici benedicti. The synthesized Au-CuO and CuO-ZnO nanoparticles were also analyzed in terms of their antibacterial activity, as well as their influence on cell viability, using two specific cell lines: C6 rat brain glioma (ATCC® CCL-107™) and T98G human glioma (ATCC® CRL-1690™). The studies carried out by means of Atomic Force Microscopy helped to determine the presence Au-CuO nanoparticles whose size was about 13 nm. The size of CuO-ZnO nanoparticles was about 28 nm. The obtained nanoparticles showed cidal activity against glioma cells depending on the concentration of the substance and the time of culture. In the first stage, the nanoparticles limited the ability to divide cells; then, they blocked the cell cycle in the G2 – M phase, and finally led to massive cell death. The antimicrobial activity studies showed that Au-CuO nanoparticles inhibited the growth of microorganisms at lower concentrations than CuO-ZnO nanoparticles, and both kinds of nanoparticles showed excellent cidal properties. Keywords: Metal nanoparticles, Antimicrobial activity, Anticancer activit

Hepatitis E virus IgG seroprevalence in HIV patients and blood donors, west-central Poland

Objective: To assess hepatitis E virus (HEV) seroprevalence in HIV patients and blood donors from one region in Poland. Methods: A group of 490 persons (244 HIV patients and 246 blood donors) aged 18–55 years were examined using the anti-HEV IgG assay (Wantai Biological Pharmacy Enterprise, Beijing, China). An analysis of the association between certain factors and the presence of this HEV exposure marker was conducted in both groups. Results: An HEV seropositivity rate of 50.2% was found. There was no difference in HEV seroprevalence between blood donors (49.6%, 122/246) and HIV patients (50.8%, 124/244) (p = 0.569). The anti-HEV IgG positivity rate increased with age as follows: 36.2% (59/163) in persons aged 18–30 years, 52.0% (92/177) in individuals aged 31–40 years and 63.3% (95/150) in those aged 41–55 years. HEV infection occurred in 56.4% (31/55) of people who had never travelled abroad. Conclusions: Wielkopolska Region in west-central Poland is an area hyperendemic for HEV infection. In this part of Poland, the exposure of HIV-positive persons to this virus is not greater than that of healthy blood donors

Comparative Seroprevalence of Hepatitis A And E Viruses in Blood Donors from Wielkopolska Region, West-Central Poland

The objective of the present study was to investigate the seroprevalence of HAV and HEV in Polish blood donors (BDs). One hundred and ten randomly selected healthy BDs, living in Wielkopolska Region were tested for anti-HAV IgG and anti-HEV IgG with commercial assays. The seroprevalence of anti-HAV was 11.8%; anti-HEV were detected in 60.9% of BDs (p < 0.0001). Consumption of risky food was more common in anti-HEV-positive BDs (59.1% vs. 33.3%; p = 0.01). Twelve out of 20 BDs (60%) with no history of travel abroad were exposed to HEV. Wielkopolska Region, Poland should be regarded as a new HEV infection-hyperendemic area in Europe

Immunity after HPV vaccination in patients after sexual initiation

Vaccinations against human papillomavirus (HPV) are included in the primary prevention of precancerous intraepithelial lesions and HPV-related cancers. Despite the undeniable effectiveness of vaccination in the juvenile population, there is still little research on the effect in patients after sexual initiation. Our study aims to assess anti-HPV (L1 HPV) antibodies in healthy patients and diagnosed cervical pathology after 9-valent vaccination. We provide a prospective, ongoing 12-month, non-randomised pilot study in which 89 subjects were enrolled. We used an enzyme-linked immunosorbent assay to determine IgG class antibodies to HPV. We noted significantly higher levels of antibodies in vaccinated individuals than in the unvaccinated control group. The above work shows that vaccination against HPV might be beneficial in patients after sexual initiation as well as in those already diagnosed with HPV or SIL infection